GeneDx Holdings Corp (WGS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and …

GuruFocus News

Tue, February 24, 2026 at 6:00 AM GMT+9 4 min read

In this article:

WGS

+6.12%

This article first appeared on GuruFocus.

**Quarterly Revenue:** $121 million, up 27% year-over-year.

**Full Year Revenue:** $428 million.

**Exome and Genome Revenue:** $104 million in Q4, a 32% increase year-over-year.

**Organic Growth Rate for Exome and Genome Revenue:** 42% excluding a $6.8 million one-time payer recovery in Q4 last year.

**Exome and Genome Test Results:** 27,761 in Q4, with growth rates accelerating from 24% in Q1 to 34% by Q4.

**Average Reimbursement Rate (ARR):** Approximately $3,750 in Q4.

**Adjusted Gross Margin:** 71% for both Q4 and full year 2025.

**Adjusted Net Income:** $4.4 million for Q4 and $4.8 million for the full year.

**2026 Revenue Guidance:** $540 million to $555 million.

**2026 Exome and Genome Volume Growth Guidance:** 33% to 35%.

**2026 Adjusted Gross Margin Guidance:** Approximately 70%.

Warning! GuruFocus has detected 3 Warning Sign with WGS.

Is WGS fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 23, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

GeneDx Holdings Corp (NASDAQ:WGS) reported strong quarterly revenues of $121 million, marking a 27% year-over-year increase.

Exome and genome revenues grew by 32% year-over-year, with an organic growth rate of 42% when excluding a one-time payer recovery.

The company has reaffirmed its full-year 2026 guidance, projecting total revenues between $540 million to $555 million.

GeneDx has a significant competitive advantage with its Infinity data set, the world's largest and most diverse rare disease data set.

The company is expanding its sales force significantly, nearly tripling it to capture growth opportunities in untapped markets.

Negative Points

The company faces challenges with high denial rates in new outpatient markets, which could impact reimbursement rates.

Weather-related disruptions have affected test volumes, with potential impacts on quarterly performance.

Despite a strong sales force, there is still a significant portion of the market that remains untapped, indicating potential barriers to adoption.

The NICU market, while promising, has shown slower-than-expected ramp-up in ordering patterns.

GeneDx is in a phase of heavy investment, which may impact short-term profitability as the company prioritizes market capture over immediate margin optimization.

Q & A Highlights

Q: Your guidance assumes a significant increase in foundational tests. What is driving this, and what gives you confidence in this assumption? A: Kevin Feeley, CFO: There are several factors, including the potential to activate new clinicians and increase orders from existing ones. We’ve focused on a few cohorts of doctors and indications, but there’s a wider range of tests that will be ordered over time. Our commercial team is strong, and we’re nearly tripling its size to move the paradigm towards exome and genome testing.

Story Continues  

Q: Can you discuss the quarterly cadence for volumes, ASPs, and gross margins this year? A: Kevin Feeley, CFO: Q1 is typically the low point for volume and reimbursement rates due to deductible resets and weather impacts. We expect Q4 to be the strongest. Gross margins ended the year at 71%, with exome and genome portfolios operating significantly stronger. We expect genome costs to decrease as utilization ramps up.

Q: How are you thinking about the potential impact of HR 7118 and other legislative opportunities on pricing? A: Kevin Feeley, CFO: We have not included any uplift from national legislation in our 2026 outlook. While there’s great reception among policymakers, we need clearer line of sight before including it in our expectations. However, we continue to see progress at state levels for biomarker bills and Medicaid coverage expansion.

Q: Can you provide more color on the growth contribution from new markets like NICU and prenatal? A: Kevin Feeley, CFO: NICU is expected to be the largest contributor from expansion markets in 2026. We’re seeing early signs of increased utilization. Prenatal is a big opportunity, but we expect volumes to ramp gradually, with more significant growth in the second half of the year.

Q: How are you addressing competition in the market, and what steps are you taking to maintain your leadership position? A: Katherine Stueland, CEO: Competition validates the market size and helps educate clinicians. We have a large sales force and continue to invest in R&D to maintain our competitive edge. Our Infinity data set ensures accurate testing, and we focus on fast turnaround times and cost-effectiveness to stay ahead.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info